Search Results - "Littlefield, Christopher"

Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape by Martin, Constance J, Datta, Abhishek, Littlefield, Christopher, Kalra, Ashish, Chapron, Christopher, Wawersik, Stefan, Dagbay, Kevin B, Brueckner, Christopher T, Nikiforov, Anastasia, Danehy, Jr, Francis T, Streich, Jr, Frederick C, Boston, Christopher, Simpson, Allison, Jackson, Justin W, Lin, Susan, Danek, Nicole, Faucette, Ryan R, Raman, Pichai, Capili, Allan D, Buckler, Alan, Carven, Gregory J, Schürpf, Thomas

“…Despite breakthroughs achieved with cancer checkpoint blockade therapy (CBT), many patients do not respond to anti-programmed cell death-1 (PD-1) due to…”
Get more information

P2-176: Functional and high-content cell-based assays of tau phosphorylation and microtubule binding by Littlefield, Christopher M, Chan, Grace K.Y, Kariv, Ilona, Szewczak, Alexander A, Hutton, Michael, Shearman, Mark, Nuthall, Hugh

Get full text

An antibody that inhibits TGF-β1 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis by Jackson, Justin W, Frederick C Streich, Jr, Pal, Ajai, Coricor, George, Boston, Chris, Brueckner, Christopher T, Canonico, Kaleigh, Chapron, Christopher, Cote, Shaun, Dagbay, Kevin B, Danehy, Jr, Francis T, Kavosi, Mania, Kumar, Sandeep, Lin, Susan, Littlefield, Christopher, Looby, Kailyn, Manohar, Rohan, Martin, Constance J, Wood, Marcie, Zawadzka, Agatha, Wawersik, Stefan, Nicholls, Samantha B, Datta, Abhishek, Buckler, Alan, Schürpf, Thomas, Carven, Gregory J, Qatanani, Mohammed, Fogel, Adam I

“…Inhibitors of the transforming growth factor-β (TGF-β) pathway are potentially promising antifibrotic therapies, but nonselective simultaneous inhibition of…”
Get more information

Abstract 4090: Defeating primary checkpoint resistance: SRTβ1-Ab3 is a first-in-class, fully human antibody that renders resistant tumors sensitive to anti-PD-1 by Schürpf, Thomas, Martin, Constance J., Littlefield, Christopher, Chapron, Christopher, Wawersik, Stefan, Kalra, Ashish, Simpson, Allison, Danehy, Francis, Boston, Christopher, Nikiforov, Anastasia, Lin, Susan, Jackson, Justin, Carven, Gregory J., Buckler, Alan, Datta, Abhishek

“…Despite the clinical breakthroughs achieved by checkpoint blockade therapy (CBT), a majority of patients treated with PD-(L)1 inhibitors fail to respond due to…”
Get full text